Observing the effects of cannabis products on immune support
Official title: Commercially Available Cannabis (Hemp) Products for Immune Support: A Prospective Observational Study to Evaluate Safety and Effects
Run by Center For Interventional Pain and Spine · NCT05944705 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is looking at how using hemp and cannabis products for immune support affects people with infections like the flu and COVID-19.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Center For Interventional Pain and Spine Academic / other |
| Locations | 1 site (Bryn Mawr, Pennsylvania) |
| Trial ID | NCT05944705 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are active participants in the Pennsylvania medical marijuana program and currently experiencing symptoms of an acute illness.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or planning to become pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to track the use of commercially available hemp and cannabis products marketed for immune support among individuals experiencing acute infections like influenza and COVID-19. Participants will be monitored for their consumption of these products and the associated effects on their symptoms. The study seeks to understand the safety and efficacy of cannabis in real-world settings, particularly given the rapid acceptance of these products in the market. By utilizing a prospective observational design, the research aims to provide insights comparable to randomized controlled trials, despite the inherent limitations of observational studies.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and efficacy of cannabis products for immune support during acute infections.
How similar studies have gone: While observational studies on cannabis use are becoming more common, this specific approach to studying commercially available products for immune support is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age or older 2. Able to read and write in English 3. Active participants in the Pennsylvania medical marijuana program (for cannabis product users) 4. Currently experiencing one or more of the following symptoms due to an acute illness: 1. Fever or chills 2. Cough 3. Fatigue 4. Muscle or body aches 5. Headache 6. Sore throat 7. Congestion or runny nose 8. Nausea or Vomiting 9. Diarrhea 5. Agrees to consume their chosen hemp or cannabis product (for the cannabis arm) and to not use a different hemp or cannabis product through the duration of the study 6. Agrees to continue to abstain from using hemp or cannabis (for the non-cannabis/hemp using arm) 7. Must have smart phone or email and access to the internet 8. Be able to comply with study requirements including baseline, completion of electronic questionnaires, and study timeline parameters. Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant. 2. Known allergy to any compounds in hemp or cannabis. 3. Endorses suicidal intent 4. Immunocompromised individuals 5. Unwilling or unable to comply with study procedures 6. Terminal Illness with life expectancy less than 1 year
Where it's running
-
Center for Interventional Pain and Spine
Bryn Mawr, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Philip Kim, MD — Center For Interventional Pain and Spine
- Study coordinator: Ashley M Scherer, MS
- Email: ashleys@centerisp.com
- Phone: 3027503099
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults
This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.
-
Virological Monitoring of Seasonal Respiratory Infections in France
This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.
-
Understanding how brain changes relate to smell disorders over time
This small, year-long study tests how brain activity and smell-related inflammation relate to different smell disorders in adults.
-
Monitoring and detection of influenza, RSV, and COVID-19 in adults with and without HIV in Lusaka
This project will test methods to detect influenza, RSV, and COVID-19 in adults with and without HIV who have recent respiratory symptoms in Lusaka.
-
Evaluating COVID-19 and influenza vaccine schedules for immunocompromised individuals
This study is testing different ways to give COVID-19 and flu vaccines to people with weakened immune systems to see which method works best for their protection.
-
A program to empower community health workers to combat vaccine misinformation
This study is testing a program that helps community health workers from Hispanic backgrounds use their personal stories to fight vaccine misinformation and boost vaccination rates in their communities.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.